Assessing the available techniques for testing myocardial viability: what does the future hold?

Brian P Shapiro1, Patricia J Mergo, Christopher O Austin

  • 1Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA. shapiro.brian@mayo.edu

Future Cardiology
|November 27, 2012
PubMed

Insights

Assessing myocardial viability is crucial for patients with severe coronary artery disease and left ventricular dysfunction. Viability testing may guide treatment decisions, though its impact on long-term survival remains under investigation.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Cardiovascular Disease

Background:

  • Severe coronary artery disease (CAD) with left ventricular dysfunction presents a complex clinical challenge.
  • Patients with CAD and reduced ejection fraction have poor prognoses, but outcomes vary after revascularization.
  • Irreversibly scarred myocardium may not benefit from revascularization, unlike viable but hibernating myocardium.

Purpose of the Study:

  • To review the role and current evidence regarding myocardial viability testing in patients with ischemic cardiomyopathy.
  • To discuss the potential benefits and limitations of viability assessment in guiding therapeutic strategies.
  • To highlight emerging technologies in the field of viability testing.

Main Methods:

  • Review of existing literature on myocardial viability testing in ischemic cardiomyopathy.
  • Discussion of various noninvasive imaging modalities for assessing myocardial viability.
  • Consideration of the predictive value of viability testing for functional recovery and prognosis.

Main Results:

  • Myocardial viability testing can predict regional and global functional recovery of the left ventricle.
  • The ability of current viability studies to predict long-term survival and overall prognosis is not yet definitively proven in prospective studies.
  • Some patients with hibernating myocardium may benefit from revascularization, while those with transmural infarction are less likely to recover function.

Conclusions:

  • Myocardial viability testing is a valuable tool for selecting patients who may benefit from revascularization, despite inconclusive data on survival benefits.
  • Noninvasive viability assessment aids in tailoring treatment strategies for patients with ischemic cardiomyopathy.
  • Advancements in imaging technologies like PET and cardiac MRI are expected to further refine viability assessment in the future.